Market Overview

Bristol-Myers Squibb CompanyNew Longer-Term Data for Empliciti Showed Continued Progression-Free Survival Benefit in Patients with Relapsed or Refractory Multiple Myeloma #ASH2015


Squibb Company (NYSE: BMY) today presented extended follow-up
data and a pre-specified interim overall survival (OS) analysis of Empliciti
in combination with Revlimid® (lenalidomide) and
dexamethasone (ERd) in patients with relapsed or refractory multiple
myeloma from ELOQUENT-2. The follow-up data demonstrated that Empliciti
in combination with Rd had an improvement in progression-free
survival (PFS) with a hazard ratio (HR) of 0.73 (95% CI: 0.60, 0.89;
p=0.0014) versus Rd alone. This result was consistent with the
improvement in PFS that was observed at the time of the primary analysis
(HR 0.70 [95% CI: 0.57, 0.85; p = 0.0004]).

The Empliciti combination delayed the need for subsequent myeloma
therapy by

See full press release

Posted-In: News Press Releases


Related Articles (BMY)

View Comments and Join the Discussion!